- cafead Jul 08, 2024 at 11:52: AM
via Pharma giant AstraZeneca and UK biotech Aptamer Group are hoping to bolster the efficacy of small interfacing RNA (siRNA) therapies, using Aptamer’s Optimer delivery system.
The companies did not disclose the financials behind the collaboration but following the 3 July announcement, Aptamer’s shares were up by 18% to $0.95 (£0.74).
article source
The companies did not disclose the financials behind the collaboration but following the 3 July announcement, Aptamer’s shares were up by 18% to $0.95 (£0.74).
article source